ARCHIVES

Risk-Benefit Analysis Advised Prior To Hormone Therapy

This article is from The Cancer Letter archive.

Vol. 33 No. 8 | August 27, 2010

Download PDF Visit The Full Archive

Related Articles

Also AIDS Malignancy Consortium grants to be consolidated on recompetition to one central group chairman’s office.

November 19, 2004

FTE Shortage Hurting Cancer and AIDS Research, Advisors Told; NCI Seeks Major Share Of New Slots

October 14, 1988

NCAB Subcommittee Approves Compromise On Changes In Organ Site Program

April 9, 1982

Two Drugs Slow Progress Of Metastatic Prostate Cancer

June 29, 2001

House Committee Investigates ESA Safety, Urges Amgen, J&J, To Stop Promotions.

March 23, 2007

UPCI Recruits Shin To Lead Head & Neck Cancer Program.

April 27, 2001